Clinical Trials Browser

Phase 1 × INDUSTRY × Platinum Resistant Ovarian Cancer × Clear all

NCT06517433 2024-07-24

First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b

Phase 1 Completed

GynecologicThoracic

Platinum Resistant Ovarian Cancer

NCT06517485 2024-07-24

First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b

Phase 1 Completed

Platinum Resistant Ovarian Cancer